Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Preliminary activity of XL880, a dual MET/VEGFR2 inhibitor, in MET amplified poorly differentiated gastric cancer (PDGC): Interim results of a multicenter phase II study Jhawer, M. P., Kindler, H. L., Wainberg, Z. A., Hecht, J. R., Kerr, R. O., Ford, J. M., Henderson, C., Mueller, T., KEER, H. N., Shah, M. A. AMER SOC CLINICAL ONCOLOGY. 2008
View details for Web of Science ID 000208457401683